Correction to Biogen Treads Tricky Path Between Politicians, Investors Article
19 Août 2017 - 1:19AM
Dow Jones News
Data published by the National Multiple Sclerosis Society show
that Biogen, along with rival companies such as Teva Pharmaceutical
Industries and Novartis Pharmaceuticals, haven't been shy about
raising the list prices of these medicines. "Biogen Treads Tricky
Path Between Politicians, Investors," at 10:43 a.m. EDT, in the
third paragraph incorrectly included Roche Pharmaceuticals among
the companies that have raised the list prices of their multiple
sclerosis medicines.
(END) Dow Jones Newswires
August 18, 2017 19:04 ET (23:04 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
